Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer.

Chaobin He,Yu Zhang,Zhiyuan Cai,Shengping Li,Xin Huang,Xiaojun Lin

doi:10.3389/fonc.2020.00006

Abstract

Locally advanced pancreatic cancer (LAPC) has a dismal prognosis even after standard chemotherapy, and local progression contributes to nearly one-third of the deaths of these patients. As a local destructive method, irreversible electroporation (IRE) can feasibly treat LAPC. The aim of this study was to evaluate IRE combined with chemotherapy as a new treatment and compare its efficacy with that of chemotherapy alone in patients with LAPC. The data of LAPC patients who received chemotherapy with or without IRE were extracted from Surveillance, Epidemiology, and End Results (SEER) database and medical records of Sun Yat-sen University Cancer Center (SYSUCC). The efficacy of these two treatments was compared using propensity score matching (PSM) analysis. LAPC patients treated with the combination therapy had better overall survival (OS). Significantly higher cancer-specific survival (CSS) and progression-free survival (PFS) rates were also observed in patients after IRE combined with chemotherapy, compared with chemotherapy alone. IRE combined with chemotherapy was established as a favorable factor for OS, CSS, and PFS in LAPC patients. This combination method may be a more suitable treatment for patients with LAPC.

Highlights

irreversible electroporation (IRE) Plus Chemotherapy in Locally advanced pancreatic cancer (LAPC) (CA19-9), which were the same as those in our previous reports [11], were investigated in this study
Higher cancer-specific survival (CSS) and progression-free survival (PFS) rates were observed in patients after IRE combined with chemotherapy, compared with chemotherapy alone
The Sun Yat-sen University Cancer Center (SYSUCC) cohort consisted of patients who were initially treated with chemotherapy alone or induction chemotherapy followed by IRE from August 2015 to August 2017

Summary

Introduction

IRE Plus Chemotherapy in LAPC (CA19-9), which were the same as those in our previous reports [11], were investigated in this study. OS, cancer-specific survival (CSS), and progression-free survival (PFS), which were defined as the duration from the date of treatment to death from all causes, cancer-related deaths, and tumor progression, respectively, or last follow-up. September 30, 2018 was the last date of follow-up. On small cohorts of patients and had contradictory results [7, 8]. Prospective data for combination therapy of IRE and chemotherapy in clinical trials is still lacking. It is necessary to fill this gap with new information on the clinical and treatment characteristics of a large cohort of patients with LAPC. The Surveillance, Epidemiology, and End Results (SEER)

Objectives

Methods

Results

Conclusion